Recorded fracture liaison service plus discharge zoledronic acid prescription and 730-day refracture risk after surgically treated vertebral fracture in older adults: a target-trial-informed discharge landmark analysis.
- 1Department of Spine Surgery, Anhui No. 2 Provincial People's Hospital, Hefei, Anhui, China.
- 2The First Affiliated Hospital of Anhui University of Science and Technology, Huainan, Anhui, China.
- 3Department of Clinical Medicine, Wannan Medical University, Wuhu, Anhui, China.
Abstract
Hospitalization for vertebral fracture offers an opportunity to connect acute care with secondary fracture prevention. We examined whether recorded fracture liaison service (FLS) use plus a positive discharge zoledronic acid (ZOL) prescription/dispensing field was associated with lower postdischarge refracture risk. Using a public fracture registry from Kunshan, China, we included patients aged 65 years or older admitted between 2019 and 2021 with a surgically treated thoracic or lumbar vertebral fracture. Eligible patients were alive and refracture-free at discharge, with discharge defining the landmark time zero. We compared recorded FLS plus a positive discharge ZOL prescription (pathway) against neither a recorded FLS nor a discharge ZOL/alendronate (comparator). Fifty-fold multiple imputation and ridge propensity score overlap weighting addressed missing measured covariates and group differences. Weighted Aalen-Johansen estimation treated death as a competing event. Confidence intervals (CIs) were derived from 1,000 patient-level bootstrap replicates. The cohort included 585 patients (266 pathway; 319 comparator), with 37 refractures and 26 deaths before refracture. The maximum weighted absolute standardized mean difference was 0.046 for fitted propensity terms and 0.087 for the common clinical panel across imputations. Estimated 730-day refracture risks were 2.40% (95% CI, 0.76%-4.31%) and 7.02% (95% CI, 4.12%-10.29%), respectively. The risk difference was -4.63 (95% CI, -8.38 to -1.24) percentage points and the risk ratio was 0.34 (95% CI, 0.10-0.76). Reduced and alternative propensity specifications yielded similar associations, although some left greater residual imbalance. The extended 2019-2022 analysis (n = 770) at 365 days was less conclusive [risk difference, -1.24 (95% CI, -3.62 to 1.07) percentage points]. Among older surgically treated vertebral fracture inpatients, recorded FLS plus positive discharge ZOL prescription was associated with lower estimated 730-day refracture incidence. This pathway-level observational association does not establish the independent effects of FLS or ZOL or confirm drug administration. Limited events and unmeasured treatment selection factors warrant cautious interpretation.
Related
- Storage and Disposal of Unused Prescription Opioids for Acute Pain After Emergency Department Discharge.
- Changes in bone density and metabolism marker levels in type I Gaucher's disease following annual zoledronic acid hydrate administration: A case report
- Clinical outcomes and safety of zoledronic acid in castration-resistant metastatic prostate cancer with bone metastases: real-world data from Côte d’Ivoire
- Efficacy and safety of neoadjuvant targeted therapy in surgically treated patients with ALK-rearranged non-small cell lung cancer
- Bowel preparation for colonoscopy in patients with surgically altered anatomy: a narrative review and institutional protocol
BibTeX
@article{gao2026recorded,
title = {{Recorded fracture liaison service plus discharge zoledronic acid prescription and 730-day refracture risk after surgically treated vertebral fracture in older adults: a target-trial-informed discharge landmark analysis.}},
author = {Ke Gao and Gang Zhang and Haoran Lu and Xiangyang Liu and Yubing Zhang},
journal = {Frontiers in medicine},
year = {2026},
month = oct,
doi = {10.3389/fmed.2026.1972395},
url = {https://europepmc.org/article/MED/42952628},
note = {CC BY},
}
RIS
TY - JOUR
TI - Recorded fracture liaison service plus discharge zoledronic acid prescription and 730-day refracture risk after surgically treated vertebral fracture in older adults: a target-trial-informed discharge landmark analysis.
AU - Ke Gao
AU - Gang Zhang
AU - Haoran Lu
AU - Xiangyang Liu
AU - Yubing Zhang
PY - 2026
DA - 2026/10/14
JO - Frontiers in medicine
DO - 10.3389/fmed.2026.1972395
UR - https://europepmc.org/article/MED/42952628
AB - Hospitalization for vertebral fracture offers an opportunity to connect acute care with secondary fracture prevention. We examined whether recorded fracture liaison service (FLS) use plus a positive discharge zoledronic acid (ZOL) prescription/dispensing field was associated with lower postdischarge refracture risk. Using a public fracture registry from Kunshan, China, we included patients aged 65 years or older admitted between 2019 and 2021 with a surgically treated thoracic or lumbar vertebral fracture. Eligible patients were alive and refracture-free at discharge, with discharge defining the landmark time zero. We compared recorded FLS plus a positive discharge ZOL prescription (pathway) against neither a recorded FLS nor a discharge ZOL/alendronate (comparator). Fifty-fold multiple imputation and ridge propensity score overlap weighting addressed missing measured covariates and group differences. Weighted Aalen-Johansen estimation treated death as a competing event. Confidence intervals (CIs) were derived from 1,000 patient-level bootstrap replicates. The cohort included 585 patients (266 pathway; 319 comparator), with 37 refractures and 26 deaths before refracture. The maximum weighted absolute standardized mean difference was 0.046 for fitted propensity terms and 0.087 for the common clinical panel across imputations. Estimated 730-day refracture risks were 2.40% (95% CI, 0.76%-4.31%) and 7.02% (95% CI, 4.12%-10.29%), respectively. The risk difference was -4.63 (95% CI, -8.38 to -1.24) percentage points and the risk ratio was 0.34 (95% CI, 0.10-0.76). Reduced and alternative propensity specifications yielded similar associations, although some left greater residual imbalance. The extended 2019-2022 analysis (n = 770) at 365 days was less conclusive [risk difference, -1.24 (95% CI, -3.62 to 1.07) percentage points]. Among older surgically treated vertebral fracture inpatients, recorded FLS plus positive discharge ZOL prescription was associated with lower estimated 730-day refracture incidence. This pathway-level observational association does not establish the independent effects of FLS or ZOL or confirm drug administration. Limited events and unmeasured treatment selection factors warrant cautious interpretation.
SN - 2296-858X
ER -